Gemfibrozil

Increases risk of myopathy and rhabdomyolysis when used with ATORVALIQ. Concomitant use is not recommended.

Increases risk of myopathy and rhabdomyolysis when used with atorvastatin. Concomitant use is not recommended.

Strong CYP2C8 inhibitor causing marked increase in daprodustat exposure. Contraindicated with DAPRODUSTAT.

Dasabuvir: Co-administration of gemfibrozil with dasabuvir increased dasabuvir AUC and C max (ratios: 11.3 and 2.01, respectively) due to CYP2C8 inhibition. Increased dasabuvir exposure may increase the risk of QT prolongation, therefore, co-administration of gemfibrozil with dasabuvir is contraindicated (see CONTRAINDICATIONS ).

Contraindicated due to increased risk of myopathy and rhabdomyolysis with ezetimibe and simvastatin tablets.

Concomitant administration increases risk of myopathy and rhabdomyolysis. Should be avoided.

Increased risk of myopathy and rhabdomyolysis when used concomitantly with fluvastatin. Avoid concomitant use.

UGT1A1 inhibitor may increase systemic exposure to irinotecan or SN-38. Do not administer unless no therapeutic alternatives.

Concomitant administration should be avoided due to significantly increased risk of myopathy/rhabdomyolysis.

Gemfibrozil significantly increased repaglinide exposures by 8.1 fold. Do not administer repaglinide to patients receiving gemfibrozil.

Strong CYP2C8 inhibitor; concomitant use not recommended as it increases resmetirom Cmax and AUC, increasing risk of adverse reactions.

Combination should be avoided due to increased risk of myopathy/rhabdomyolysis. If used together, limit rosuvastatin to 10 mg once daily.

Strong CYP2C8 inhibitor that doubled selexipag exposure and increased active metabolite exposure approximately 11-fold. Concomitant use is contraindicated.

Drug Interactions ( A) HMG-CoA Reductase Inhibitors: The concomitant administration of gemfibrozil with simvastatin is contraindicated (see CONTRAINDICATIONS and WARNINGS ). Combination therapy of gemfibrozil with simvastatin or with repaglinide, which are OATP1B1 substrates, is contraindicated (see CONTRAINDICATIONS ).

Strong CYP2C8 inhibitor significantly increases pioglitazone exposure and half-life. Maximum recommended dose limited to 25 mg alogliptin and 15 mg pioglitazone daily.

Concomitant administration increases plasma concentrations of bexarotene. Concomitant use is not recommended.

Lipid-lowering drug with potential for pharmacokinetic/pharmacodynamic interaction causing myopathy and rhabdomyolysis. Monitor for muscle pain.

Absorption of gemfibrozil is significantly decreased when given simultaneously with colestipol hydrochloride.

Strong CYP2C8 inhibitor may increase iptacopan exposure and increase risk for adverse reactions. Coadministration not recommended.

Combined with gemfibrozil, itraconazole resulted in synergistic increase of repaglinide AUC (19.4-fold) and plasma concentration (70.4-fold), prolonging hypoglycemic effects.

CYP2C8 inhibitor increases loperamide peak plasma concentration 1.6-fold and systemic exposure 2.2-fold, increasing risk for cardiac adverse reactions.

Lipid-lowering drug that can cause myopathy alone; increases risk of myopathy when given with lovastatin.

Strong CYP2C8 inhibitor significantly increases pioglitazone exposure and half-life, requiring dose reduction to maximum 15 mg pioglitazone and 850 mg metformin daily.

Strong CYP2C8 inhibitor significantly increases pioglitazone exposure and half-life. Maximum pioglitazone dose limited to 15 mg daily.

Strong CYP2C8 inhibitor significantly increases pioglitazone exposure and half-life. Maximum pioglitazone dose must be limited to 15 mg daily.

Strong CYP2C8 inhibitor that significantly increases pioglitazone exposure and half-life. Maximum pioglitazone dose must be limited to 15 mg daily.

Gemfibrozil may cause myopathy when given alone. Risk of myopathy and rhabdomyolysis is increased with concomitant use with pitavastatin.

Gemfibrozil increases the risk of myopathy and rhabdomyolysis when used concomitantly with pitavastatin. Concomitant use should be avoided.

Gemfibrozil may cause myopathy when given alone. Risk of myopathy and rhabdomyolysis is increased with concomitant use with pitavastatin.

Avoid concomitant use of gemfibrozil with rosuvastatin. If concomitant use cannot be avoided, initiate rosuvastatin at 5 mg once daily. The dose of rosuvastatin should not exceed 10 mg once daily.

Caution when used together; warfarin dosage should be reduced and prothrombin time monitored to prevent bleeding complications.

OATP1B1 substrate; gemfibrozil inhibition may increase atorvastatin exposure, requiring dosing reduction.

OATP1B1 substrate; gemfibrozil inhibition may increase atrasentan exposure, requiring dosing reduction.

OATP1B1 substrate; gemfibrozil inhibition may increase bosentan exposure, requiring dosing reduction.

OATP1B1/1B3 inhibitor increases brincidofovir AUC and Cmax, may increase adverse reactions. Monitor for elevations in transaminases, bilirubin, diarrhea, or GI events.

Other lipid-lowering drug that may interact with colchicine. Monitor patients during coadministration.

Gemfibrozil is a strong CYP2C8 inhibitor that may increase dabrafenib exposure; dosing reduction may be required.

OATP1B1 inhibitor that may increase eluxadoline exposure. Requires monitoring for adverse reactions and potential dose adjustment.

Gemfibrozil is a strong CYP2C8 inhibitor that may increase enzalutamide exposure; dosing reduction may be required.

OATP1B1 substrate; gemfibrozil inhibition may increase ezetimibe exposure, requiring dosing reduction.

OATP1B1 substrate; gemfibrozil inhibition may increase glyburide exposure, requiring dosing reduction.

OATP1B1 substrate (active metabolite SN-38); gemfibrozil inhibition may increase irinotecan exposure, requiring dosing reduction.

Gemfibrozil is a strong CYP2C8 inhibitor that may increase loperamide exposure; dosing reduction may be required.

Gemfibrozil is a strong CYP2C8 inhibitor that may increase montelukast exposure; dosing reduction may be required.

OATP1B1 substrate; gemfibrozil inhibition may increase olmesartan exposure, requiring dosing reduction.

CYP2C8 inhibitor; caution should be exercised when administering paclitaxel concomitantly.

OATP1B1 substrate; gemfibrozil inhibition may increase pravastatin exposure, requiring dosing reduction.

OATP1B1 substrate; gemfibrozil inhibition may increase rifampin exposure, requiring dosing reduction.

Gemfibrozil is a strong CYP2C8 inhibitor that may increase rosiglitazone exposure; dosing reduction may be required.

CYP2C8 inhibitor increases treprostinil exposure (Cmax and AUC). Monitor for increased treprostinil effects.

OAT3 inhibitor may increase vadadustat AUC, increasing risk of adverse reactions. Monitor for rapid hemoglobin increase and adverse effects.

OATP1B1 substrate; gemfibrozil inhibition may increase valsartan exposure, requiring dosing reduction.

No dose adjustment needed when co-administered with montelukast sodium.